185 results on '"Fling, Steven P."'
Search Results
2. T antigen-specific [CD8.sup.+] T cells associate with PD-1 blockade response in virus-positive Merkel cell carcinoma
3. Merkel cell polyomavirus-specific and CD39+CLA+ CD8 T cells as blood-based predictive biomarkers for PD-1 blockade in Merkel cell carcinoma
4. Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy
5. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
6. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
7. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
8. New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy
9. Exacerbation of CMV and Nontuberculous Mycobacterial Infections Following PD-1 Blockade for HIV-Associated Kaposi Sarcoma
10. Pembrolizumab in mycosis fungoides with PD-L1 structural variants
11. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
12. Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets
13. Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
14. A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma.
15. A multiplexed assay for quantifying immunomodulatory proteins supports correlative studies in immunotherapy clinical trials
16. CD8 + T cells Recognize an Inclusion Membrane-Associated Protein from the Vacuolar Pathogen Chlamydia trachomatis
17. Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy
18. Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer
19. Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome
20. Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses
21. Functional Dissociation of T Cell Sites; Immunogenic, Antigenic and Pathogenic Sites
22. Martin A. “Mac” Cheever, MD: In Memoriam (1944–2021)
23. Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
24. PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy
25. Abstract 6669: Cellular neighborhoods predict pembrolizumab response in cutaneous T cell lymphoma
26. Abstract 4476: PD-1 and TIGIT co-expression identifies a circulating CD8 T cell population predictive of response to anti-PD-1 therapy in melanoma and Merkel-cell carcinoma patients
27. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study
28. Dynamics of the Cutaneous T Cell Lymphoma Microenvironment in Patients Treated with Pembrolizumab Revealed By Highly Multiplexed Tissue Imaging
29. Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome.
30. HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells
31. New interpretable machine learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy
32. Tuberculosis following PD-1 blockade for cancer immunotherapy
33. Durable Responses with Pembrolizumab in Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Final Results from a Phase 2 Multicenter Study
34. Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors
35. Novel Mutants Define Genes Required for the Expression of Human Histocompatibility Leukocyte Antigen DM: Evidence for Loci on Human Chromosome 6p
36. Merkel cell polyomavirus-specific and CD39+CLA+CD8 T cells as blood-based predictive biomarkers for PD-1 blockade in Merkel cell carcinoma
37. Pembrolizumab in mycosis fungoides and Sézary syndrome: Updated results of the CITN multicenter Phase 2 study
38. Gene expression markers of Tumor Infiltrating Leukocytes
39. Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study
40. Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study.
41. [CD8.sup.+] T cells recognize an inclusion membrane-associated protein from the vacuolar pathogen Chlamydia trachomatis
42. Gene expression markers of Tumor Infiltrating Leukocytes
43. CITN11-02 phase I trial of subcutaneous recombinant human IL-15 (rhIL-15) is associated with expansion of circulating CD56+ NK cells and CD8+ T cells
44. Preliminary validation of nCounter PanCancer immune profiling of FFPE slides and pbmc in CITN-05, a CITN study of the immunological effects of an IDO1 inhibitor in patients with ovarian carcinoma
45. CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhIL-15) is associated with expansion of peripheral blood CD56+ NK cells and CD8+ T cells
46. Identification of an HIV-1 Clade A Envelope That Exhibits Broad Antigenicity and Neutralization Sensitivity and Elicits Antibodies Targeting Three Distinct Epitopes
47. The ‘Ethereal’ nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics
48. A Synthetic TLR4 Antagonist Has Anti-Inflammatory Effects in Two Murine Models of Inflammatory Bowel Disease
49. Human CD8+ T Cells Recognize the 60-kDa Cysteine-Rich Outer Membrane Protein from Chlamydia trachomatis
50. An Inclusion Membrane Protein from Chlamydia trachomatis Enters the MHC Class I Pathway and Stimulates a CD8+ T Cell Response
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.